Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Verastem, Inc.NASDAQ: VSTM
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$2.85M, compared with $3.17M a year earlier. Trailing-twelve-month accounts payables was $2.4M. Over 3 fiscal years it compounded at +48.0% a year.
Context
- Accounts payables amounted to 27.2% of revenue in FY2025, down 4.3 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$2.85M or moves back toward the trailing-twelve-month quarterly average of $600.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 8.42M USD
- Year-over-year change
- +366.7%
- 4-year CAGR
- +91.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.42M | +366.7% |
| FY2024 | 2024-12-31 | (3.16M) | -238.3% |
| FY2023 | 2023-12-31 | 2.28M | -12.2% |
| FY2022 | 2022-12-31 | 2.6M | +317.2% |
| FY2021 | 2021-12-31 | 623K | — |
Accounts Payables vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 accounts payables of $2.4M is the 6th largest of the 11 companies compared; the peer median is $224K.
- Its year-over-year change of +1061.2% is the 3rd highest of 10, against a peer median of +36.6%.
- Accounts payables amounts to 4.8% of revenue for VSTM, versus a peer median of 6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $16.07M | -193.4% | — | 9.5% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $6.22M | +5837.6% | — | — |
| LTM Mar 2026 | $5.21M | +1496.2% | +17.8% | 992.0% | |
| LTM Mar 2026 | $3.89M | -608.8% | +124.3% | 23.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.48M | -265.2% | — | — |
| LTM Mar 2026 | $2.4M | +1061.2% | +48.0% | 4.8% | |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $448K | +36.6% | +70.0% | — | |
| LTM Mar 2026 | $197.49K | +121.5% | — | — | |
| LTM Mar 2026 | $92K | +109.7% | -48.0% | 0.3% | |
| LTM Jun 2024 | $0 | — | -37.3% | 0.0% | |
| Peer median (excluding VSTM) | $224K | +36.6% | -7.7% | 6.1% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Depreciation & Amortization | 72K | (36K) | 62K | 26K | 728K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M |
| Change in Working Capital | 584K | 3.9M | (957K) | 3.72M | 26M |
| Accounts Receivables | (277K) | 485K | 31K | (200K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 0 | (1.83M) |
| Accounts Payables | 623K | 2.6M | 2.28M | (3.16M) | 8.42M |
| Other Working Capital | 238K | 816K | (3.27M) | 7.08M | 28.23M |
| Other Non-Cash Items | 9.33M | 228K | (4.06M) | 14.78M | 35.83M |
| Operating Cash Flow | (53.5M) | (63.67M) | (86.46M) | (104.77M) | (137.51M) |
| Capital Expenditures | (196K) | 0 | 0 | (28K) | 0 |
| Acquisitions (Net) | 9.33M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (86.44M) | (17.82M) | (96.45M) | 0 | 0 |
| Sales of Investments | 86.73M | 84M | 52M | 60M | 29K |
| Other Investing Activities | (9.33M) | 0 | 0 | 5K | (29K) |
| Investing Cash Flow | 87K | 66.19M | (44.45M) | 59.97M | (9.62M) |
| Debt Repayment | 0 | 24.15M | 14.62M | (150K) | 32.42M |
| Common Stock Issued | 6.72M | 27.35M | 91.42M | 14.22M | 230.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 162K | 282K | 57K | 40.71M | 0 |
| Financing Cash Flow | 6.89M | 51.78M | 134.19M | 54.78M | 263.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.53M) | 54.3M | 3.29M | 9.98M | 116.17M |
| Free Cash Flow | (53.7M) | (63.67M) | (86.46M) | (104.8M) | (137.51M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.